Crucell« Terug naar discussie overzicht

1. flosz 1 oktober 2010 12:51

   auteur info

   •    flosz

     Lid sinds: 13 feb 2008

     Laatste bezoek: 01 jul 2024

   •    Aanbevelingen

     Ontvangen: 5298

     Gegeven: 2795

   •    Aantal posts: 7.005

   Hepatitis B immune memory
   Zanetti and colleagues assess immunity and the need for hepatitis B booster vaccines in children primed with the hexavalent vaccines hexavac and infanrix hexa.
   www.thelancet.com/journals/laninf/art...
   Hexavac=San.P.
   infanrix hexa=GSK
   
2. Alpen 4 oktober 2010 08:31

   auteur info

   •    Alpen

     Lid sinds: 21 mei 2008

     Laatste bezoek: 07 nov 2024

   •    Aanbevelingen

     Ontvangen: 815

     Gegeven: 100

   •    Aantal posts: 781

   Sanofi makes hostile $18.5 billion bid for Genzyme
   
   (Reuters) - French pharmaceutical giant Sanofi-Aventis (SASY.PA) launched a hostile bid for Genzyme (GENZ.O) at $69 per share, or $18.5 billion, setting off what could be a protracted battle for control of the U.S. biotech.
   
   The move comes a month after Genzyme rebuffed an approach from Sanofi-Aventis (SASY.PA) at the same price. Sanofi has been in discussions with Genzyme shareholders and stated repeatedly that it would go no higher.
   
   Sanofi said in a statement on Monday that its offer, which is all in cash, would expire on December 10 at 11:59 pm EST.
   
   "While Sanofi-Aventis' strong preference is to engage in constructive discussions with Genzyme, Genzyme's board and management team's continued refusal to do so has led Sanofi-Aventis to commence the tender offer," said Sanofi.
   
   Sanofi said its CEO Chris Viehbacher met with the CEO of Genzyme Henri Termeer on September 20, but the talks "proved unproductive."
   
   Sanofi added that it had met with Genzyme shareholders who collectively own more than 50 percent of the biotech, and that these people were frustrated with Genzyme's reticence to engage in real talks with Sanofi.
   
   In a letter dated October 4 that Viehbacher wrote to Temeer, he criticized Termeer's unwillingness to provide information about Genzyme's ongoing manufacturing issues and a promising new indication for a drug. Both questions are central to the valuation of the biotech firm's fortunes.
   
   www.reuters.com/article/idUSTRE6930RA...
   
3. [verwijderd] 4 oktober 2010 09:52

   auteur info

   •    [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   •    Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Why Sanofi’s CEO Cannot Be Trusted to Buy a Used Car
   By Jim Edwards | August 30, 2010
   .View more ..Sanofi-Aventis (SNY) has been forced to go public in its bid to buy Genzyme (GENZ) because of Sanofi CEO Chris Veihbacher’s amateurish acquisition tactics. Two things will happen now:
   
   1.Sanofi will nonetheless successfully acquire this company, assuming the company’s shareholders aren’t suddenly gripped by a collective madness that makes them walk away from a tidy profit on their stock.
   2.Viehbacher’s negotiating tactic — he declared his shopping budget of $20 billion a month before offering $18.5 billion for Genzyme — is a bit like walking onto a used-car lot and saying, “I have $10,000. Can you sell me a car?” You pretty much know that the salesman is not going to let you drive away in anything priced less than that, regardless of its actual worth.
   Sanofi’s bid is for $69 a share, or $18.5 billion. That’s a 38 percent premium if you believe Bloomberg or a 27 percent premium if you believe the Wall Street Journal.
   
   Either way, it’s a lot more money than any Genzyme shareholder is ever going to get from Genzyme. Indeed, even Genzyme CEO Henri Termeer can’t make a case that he can deliver greater value to his investors than that. His rejection note to Sanofi said that the current bid fails to value “the significant progress underway to rectify our manufacturing challenges or the potential for our new-product pipeline.” That’s a bit like a schoolchild protesting a low homework grade by saying, “this C+ doesn’t value the fact that last week’s homework got a D, and that next week’s might — might! — earn an A.”
   
   So here’s what will happen: Sanofi will make some face-saving gesture by offering slightly more than $18.5 billion, and Genzyme — having extricated a larger portion of the $20 billion Viehbacher already said he would spend — will then say yes.
   
   www.bnet.com/blog/drug-business/why-s...
   
   DRW
4. josti5 4 oktober 2010 10:15

   auteur info

   •    josti5

     Lid sinds: 23 feb 2005

     Laatste bezoek: 02 dec 2024

   •    Aanbevelingen

     Ontvangen: 17434

     Gegeven: 20819

   •    Aantal posts: 34.171

   'Sanofi added that it had met with Genzyme shareholders who collectively own more than 50 percent of the biotech, and that these people were frustrated with Genzyme's reticence to engage in real talks with Sanofi.'
   
   Yep: zo gaat dat dus...
   Zou J & J vooraf alleen de Yankees inzake de 24.75 hebben geraadpleegd, of ook van Herk, Delta e.a.?
   Over dit schimmenspel mag best duidelijkheid komen, dunkt mij.
   Enfin: Sanofi blijkt nog geld in de achterzak te hebben; hoeveel zou er nog in j & J's kontzak zitten?
   Uitgaande van Sanofi's 8%, zijn dat 2 luizige euro's boven op de 24.75.
   Genoeg voor van Herk c.s.???
   
   
5. [verwijderd] 4 oktober 2010 10:21

   auteur info

   •    [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   •    Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Crucell N.V. & Aeras Global TB Vaccine Foundation start Phase II clinical trial for (TB) vaccine candidate: www.beurstweet.nl/amx-fondsen/crucell/
6. [verwijderd] 5 oktober 2010 18:51

   auteur info

   •    [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   •    Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   MARKET TALK: European Dividend Yields Top Bond Yields-Deutsche
   
   Last update: 10/5/2010 5:47:33 AM
   
   0947 GMT [Dow Jones] Dividend yields are the best expression of equity value with interest rates so low, says Deutsche Bank. Over 60% of the market cap of the Euro Stoxx 50 index and over 50% of the market cap of FTSE 100 is at a dividend yield greater than respective government bond yields, notes the bank.
   
   "The yield offering is now so huge, a pro-equity view cannot be divorced from a pro-dividend yield strategy any longer." High-Dividend Yield is no longer a minority group but includes bluechips like Vodafone (VOD.LN), Sanofi-Aventis (SAN.FR), BASF (BAS.XE) and Royal Dutch Shell (RDSB). "Free cash-flow/ market cap for Europe overall is back up to 2004's highs," adds Deutsche.
   
   (ishaq.siddiqi@dowjones.com)
   Contact us in London. +44-20-7842-9464
   Markettalk.eu@dowjones.com
   (END) Dow Jones NewswiresOctober 05, 2010 05:47 ET (09:47 GMT)
7. pardon 6 oktober 2010 16:10

   auteur info

   •    pardon

     Lid sinds: 19 jan 2004

     Laatste bezoek: 12 sep 2022

   •    Aanbevelingen

     Ontvangen: 1387

     Gegeven: 2812

   •    Aantal posts: 16.824

   SANOFI-AVENTIS : Moody's zet ratings onder toezicht
   
   (Dow Jones) - Moody's besloot maandagavond om de ratings van Sanofi-Aventis gezet onder toezicht van een mogelijke degradatie na de lancering van een overnamebod op de Amerikaanse biotechnologiebedrijf Genzyme. Het kader van het huidige aanbod en daarmee de veronderstelling dat Sanofi 100% van Genzyme koopt, het ratingbureau verwacht lager de rating een inkeping op lange termijn. Voor nu, is Sanofi gecrediteerd met de lange termijn rating A1, de vijfde van haar indelingsschema, en korte-termijn rating van Prime
8. [verwijderd] 8 oktober 2010 11:15

   auteur info

   •    [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   •    Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   www.iex.nl/nieuws/nieuws_artikel.asp?...
   
   Sanofi en Genzyme ruzieën verder over bod
   8 okt 2010, 10:28 uur
   PARIJS (AFN) - De Franse farmaceut Sanofi-Aventis en diens beoogde overnameprooi Genzyme blijven ruzieën over de hoogte van het bod op het Amerikaanse biotechnologiebedrijf. De twee zijn al sinds mei in gesprek over een eventuele acquisitie.
   
   Volgens Genzyme gaf Sanofi-Aventis tijdens een overnamegesprek in september aan tussen de 69 en 80 dollar per aandeel te willen bieden. Donderdag schoot de koers van Genzyme in New York naar 73 dollar in de hoop op een hoger bod. Vrijdag ontkende het Franse concern die stelling.
   
   Afgelopen maandag bracht Sanofi-Aventis een vijandig bod uit op Genzyme van 69 dollar per aandeel. Het bedrijf, dat al ruim twintig jaar geleid wordt door de Nederlander Henri Termeer, wordt daarmee gewaardeerd op 18,5 miljard dollar.
9. [verwijderd] 8 oktober 2010 12:53

   auteur info

   •    [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   •    Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Zo lang kan het met Crucell ook duren, helaas geeft Viesbacher een negatief signaal af, wat wellicht door J&J overgenomen gaat worden.
   
   Sanofi-Aventis Denies Suggesting $69-$80 Range For Genzyme Bid
   
   Last update: 10/8/2010 4:20:56 AM
   
   By Mimosa Spencer Of DOW JONES NEWSWIRES PARIS
   
   (Dow Jones)--Tension between Sanofi-Aventis (SNY) and its takeover target Genzyme (GENZ) rose further Friday when the French drug giant denied that its chief executive suggested a negotiation price range to his Genzyme counterpart at a meeting last month.
   
   Genzyme Thursday filed a 14D-9 filing with the U.S. Securities and Exchange Commission which detailed the U.S. biotech's rejection of Sanofi's $18.5 billion hostile bid for the company.
   
   Sanofi launched its $69-per share offer Monday. In its filing, Genzyme revealed for the first time that during a Sept. 20 meeting, Sanofi Chief Executive Chris Viehbacher suggested to Genzyme head Henri Termeer a range of $69 a share to $80 a share to open negotiations, which Mr. Termeer rejected--a statement Sanofi contradicted Friday.
   
   "We offered no price range and Genzyme refused to engage with us on valuation," Sanofi spokesman Jean Marc Podvin told Dow Jones Newswires. He added Sanofi was not surprised by Genzyme's reaction to its bid but that it "strongly disagrees with Genzyme's characterization" of the Sept. 20 meeting between the CEOs.
   
   "At that meeting we made a variety of efforts to move the process forward including the merits of our $69 dollar per share offer and trying to understand if media reports about Genzyme's price position were accurate," Podvin said.
   
   Analysts said the public haggling over the event is a further sign of tensions between the two companies which points to a longer process for an eventual deal than previously expected. "Judging from this and previous statements from each side, we won't see a solution to this any time soon," said Jeremy Batstone-Carr, analyst with Charles Stanley, adding "This 'war of words' is likely to continue into the first quarter of next year."
   
   Analysts had said a range of up to $80 per share would have demonstrated a considerable effort on the part of Sanofi to kick start discussions.
   
   By Mimosa Spencer, Dow Jones Newswires; +33 1 40 17 1773; mimosa.spencer@dowjones.com (Sten Stovall contributed to this article.) (END)
   
   Dow Jones NewswiresOctober 08, 2010 04:20 ET (08:20 GMT)
10. josti5 8 oktober 2010 15:55

    auteur info

    •    josti5

      Lid sinds: 23 feb 2005

      Laatste bezoek: 02 dec 2024

    •    Aanbevelingen

      Ontvangen: 17434

      Gegeven: 20819

    •    Aantal posts: 34.171

    Situatie is wél verschillend: Termeer verdedigt zijn winkel, en Brus c.s. verraden 'hun' bedrijf.
    Brus: de Quisling van Crucell...
    
11. voda 8 oktober 2010 20:45

    auteur info

    •    voda

      Lid sinds: 02 dec 2005

      Laatste bezoek: 03 dec 2024

    •    Aanbevelingen

      Ontvangen: 89898

      Gegeven: 22254

    •    Aantal posts: 378.287

    Sanofi en Genzyme ruzieën verder over bod
    8 oktober 2010, 18:47 | ANP
    PARIJS (AFN) - De Franse farmaceut Sanofi-Aventis en zijn beoogde overnameprooi Genzyme blijven ruziën over de hoogte van het bod op het Amerikaanse biotechnologiebedrijf. De twee zijn al sinds mei in gesprek over een eventuele acquisitie.
    
    Volgens Genzyme gaf Sanofi-Aventis tijdens een overnamegesprek in september aan tussen de 69 en 80 dollar per aandeel te willen bieden. Donderdag schoot de koers van Genzyme in New York naar 73 dollar in de hoop op een hoger bod. Vrijdag ontkende het Franse concern die stelling.
    
    Maandag bracht Sanofi-Aventis een vijandig bod uit op Genzyme van 69 dollar per aandeel. Het bedrijf, dat al ruim twintig jaar geleid wordt door de Nederlander Henri Termeer, wordt daarmee gewaardeerd op 18,5 miljard dollar.
    
    Sanofi-Aventis maakte vrijdag bekend dat het halverwege december 1700 banen in de Verenigde Staten schrapt. De Franse farmaceut heeft in totaal 13.000 werknemers in de VS, van wie er 6900 werkzaam zijn bij de farmaceutische divisie.
    
    
12. [verwijderd] 9 oktober 2010 16:08

    auteur info

    •    [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    •    Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    En nog maar 1 uit de oude doos.
    
    January 13, 2010, 9:39 AM ET.Sanofi-Aventis CEO on Pharma’s ‘Lost Decade’.
    
    Chris Viehbacher, CEO of Sanofi-Aventis, spoke yesterday at that big drug-industry meeting in San Francisco. He described pharma’s “lost decade” of the past 10 years — for many companies, he said, share prices fell despite double-digit earnings growth.
    
    The familiar culprit: The patent cliff, and the looming revenue hits coming when big drugs like Plavix (which Sanofi co-markets with Bristol-Myers Squibb) face generic competition. And the familiar solution: to “move away from .. this boom-bust cycle that has really frustrated so many of us over the last 10 years.”
    
    FOR SANOFI, GROWTH OF THE VACCINES BUSINESS (WHICH VIEBACHER CALLED: “THE BEST BUSINESS YOU CAN BE IN”) is a key part of that diversification. The company’s recent agreement to buy Chattem will also allow it to make a big push into the U.S. over-the-counter drug business with its allergy drug Allegra. And Sanofi, which sells insulin under the Lantus brand, may also expand its diabetes business by selling services and devices, Viehbacher said.
    
    He added that the company’s R&D holds the greatest possibility for upside surprises in the next few years — because “for the most part people have zero expectations of Sanofi-Aventis research and development,” he said. “We’ve basically cleared out a lot of bad news, and if anything comes along it should be good news.”
    
13. [verwijderd] 20 oktober 2010 12:59

    auteur info

    •    [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    •    Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Sanofi-Aventis Gets US Authorization To Buy Genzyme
    
    Last update: 10/20/2010 3:49:30 AM
    
    By Sten Stovall Of DOW JONES NEWSWIRES
    
    Sanofi-Aventis (SNY) said Wednesday the U.S. anti-trust regulator has approved its plan to buy Genzyme Corp. (GENZ), giving the French pharmaceutical giant the green light to proceed with its hostile $69 per share tender offer for the biotech.
    
    Sanofi said the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976 has now expired. The act imposes a waiting period on a proposed merger during which U.S. regulators study it for possible antitrust violations. The regulator's approval is one step in the process, which is still subject to other conditions set in early October, Sanofi said. On Oct. 4, Sanofi started the process of a public tender offer for all the shares in Genzyme, valuing the Cambridge, Mass., biotech at $18.5 billion, after the target company's board repeatedly rejected the French drug giant's $69 per share offer, which Genzyme has shunned as being too low. The public takeover drama began when Sanofi sent a "bear hug" letter to Genzyme in late August laying out a non-binding offer, but that was swiftly rebuffed. Since then, Sanofi Chief Executive Chris Viehbacher has been gauging support for his company's offer by talking directly to Genzyme shareholders in a series of meetings in New York.
    
    With the Genzyme board's rejection of the offer, the outcome of Sanofi's tender offer now rests with shareholders. They can still elect to surrender their shares to Sanofi at $69, but that is unlikely because the stock is already well above that price on the open market. Genzyme shares closed Tuesday at $71.89. At 0747 GMT, Sanofi shares were down 0.6% or EUR0.28 at EUR49.62 in a broadly lower Paris market. Genzyme will later Wednesday report third-quarter earnings and investors expect its management will use that opportunity to further explain its rejection of Sanofi's overture and again advise investors not to take any action.
    
    Sanofi's offer for Genzyme--which specializes in developing drugs for rare disease--was approved unanimously by Sanofi-Aventis's board of directors and is to expire at 11.59 p.m. U.S. Eastern time on Dec. 10.
    
    -By Sten Stovall, Dow Jones Newswires; +44 207 842 9292; sten.stovall@dowjones.com (END)
    
    Dow Jones Newswires
    
    October 20, 2010 03:49 ET (07:49 GMT)
    
14. [verwijderd] 25 oktober 2010 21:04

    auteur info

    •    [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    •    Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Following Positive Phase II Data, Sanofi Pasteur to Conduct Phase III Trials of Quadrivalent Influenza Virus Vaccine
    
    Last update: 10/25/2010 8:45:00 AM
    
    SWIFTWATER, Pa., Oct 25, 2010 /PRNewswire via COMTEX/ -- Sanofi Pasteur, the vaccines division of the sanofi-aventis Group , announced today the results of a clinical trial of its investigational Fluzone(R) Quadrivalent (Influenza Virus Vaccine) compared to the currently licensed Fluzone (Influenza Virus Vaccine).
    
    Data from the Phase II trial assessing the immunogenicity and safety of the investigational quadrivalent vaccine were presented at the 48th Annual Meeting of the Infectious Diseases Society of America in Vancouver, British Columbia. In this study, sponsored by Sanofi Pasteur, quadrivalent inactivated influenza vaccine (QIV) containing two strains of type A (H1N1 and H3N2) and two strains of type B (one each from the Yamagata and Victoria lineages) was evaluated in comparison to two trivalent seasonal influenza vaccines (TIV) each containing the two strains of type A plus one of the two type B strains. The data indicated that the QIV vaccine was immunologically non-inferior to TIV for all strains and the safety profiles of QIV and TIV did not materially differ.
    
    Moreover, QIV induced responses to both B lineage strains simultaneously. "Based on the data from this trial, Sanofi Pasteur plans to proceed with Phase III clinical trials of Fluzone Quadrivalent vaccine this fall," said Wayne Pisano, President and Chief Executive Officer, Sanofi Pasteur. "We believe that Fluzone Quadrivalent vaccine could be an important vaccine for public health that may help reduce overall morbidity and mortality caused by influenza." Since influenza B Victoria lineage re-emerged worldwide in 2001-2002, both Victoria and Yamagata lineages have circulated with varying prevalence, making it difficult to predict the next season's dominant lineage. Even in years where there was a good match, some influenza disease was caused by the B lineage omitted from the vaccine. This raised the hypothesis that the addition of a second B lineage strain to expand the licensed trivalent influenza vaccine to a quadrivalent vaccine could reduce influenza morbidity and mortality.
    
    Study Design and Results The immunogenicity and safety of the quadrivalent influenza vaccine was assessed in adults 18 years of age and older in comparison to the Fluzone vaccines licensed for use during the 2008-2009 and the 2009-2010 seasons.
    
    This study design took advantage of the fact that the 2008-2009 and 2009-2010 TIVs contained identical A strains, but B strains of opposite lineages. Adult study participants (n = 570) were randomized to receive one of three study vaccines: 2008-2009 TIV (n = 190), 2009-2010 TIV (n = 190) or QIV (n = 190); and were stratified into two age groups: 18 to 61 years of age, and 61 years of age and older.
    
    Blood specimens were collected pre-vaccination and 21 to 28 days post-vaccination and standardized hemagglutination inhibition (HAI) antibody assays were performed by persons blinded to vaccine assignment to determine immunogenicity. The immunogenicity endpoints of the study were: geometric mean HAI antibody titers (GMTs), the percent of study participants with a 4-fold rise of HAI titers pre- to post-vaccination and the percent of participants with post-vaccination HAI titers greater than or equal to 1:40. Safety was an observational objective with immediate reactions monitored in the clinic for 20 minutes post vaccination, solicited systemic and injection-site reactions recorded by participants on diary cards for three days post-vaccination and unsolicited adverse events (AEs) and serious adverse events (SAEs) reported by participants from vaccination to second visit (21 to 28 days post-vaccination).
    
    The safety profiles of QIV and TIV did not materially differ as assessed by rates of solicited injection-site and systemic reactions, unsolicited AEs and SAEs. For all groups, the most frequently reported solicited injection-site reaction was pain and the most frequently reported solicited systemic reactions were myalgia, headache and malaise. In the evaluation of immunogenicity, HAI antibody responses to QIV were comparable to both licensed TIVs as assessed by GMTs, 4-fold rise rates and the percent of participants with titers greater than or equal to 1:40. QIV induced statistically non-inferior GMT responses to each A strain (H1N1 and H3N2) and each B lineage strain (Victoria and Yamagata) compared with the control TIVs containing the respective strains. About sanofi-aventis Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (FR:SAN) and in New York (SNY). For more information, please visit: Sanofi Pasteur, the vaccines division of sanofi-aventis Group, provided more than 1.6 billion doses of vaccine in 2009, making it possible to immunize more than 500 million people across the globe. A world leader in the vaccine industry, Sanofi Pasteur offers the broadest range of vaccines protecting against 20 infectious diseases. The company's heritage, to create vaccines that protect life, dates back more than a century. Sanofi Pasteur is the largest company entirely dedicated to vaccines. Every day, the company invests more than EUR 1 million in research and development.
    
    DRW
15. TonK_0 25 oktober 2010 21:08

    auteur info

    •    TonK_0

      Lid sinds: 01 jan 2000

      Laatste bezoek: 12 sep 2024

    •    Aanbevelingen

      Ontvangen: 251

      Gegeven: 12

    •    Aantal posts: 404

    Genzyme laat zien wat het waard is
    
    25 oktober | 11:15
    
    GENZYME(USD 72 - Kopen) blijft bezig om de huid duur te verkopen. Sanofi, dat Genzyme wil overnemen, had gevraagd om 'bewijs' te leveren dat het bedrijf meer waard zou zijn dan USD 69. Dat bewijs is nu geleverd.
    
    Op basis van de nieuwe prognose voor 2011 denkt Genzyme USD 4,30-USD 4,60 per aandeel te verdienen. Als dan dezelfde factor wordt toegepast die Sanofi eerder bereid was te betalen, dan zou de prijs moeten vallen tussen de USD 80 en USD 89. Sanofi wil hierover praten, maar voor Genzyme is USD 69 geen startpunt voor besprekingen.
    
    Sanofi is nu aan zet om de onderhandelingen op gang te krijgen. Het is moeilijk om te voorspellen hoe dit gaat aflopen. Weinig voorkomende ziektes zijn plotseling een aantrekkelijk aandachtspunt geworden en Genzyme is het vlaggenschip. Wij blijven het aandeel Kopen op het huidige niveau van USD 72/73.
    
16. [verwijderd] 28 oktober 2010 09:55

    auteur info

    •    [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    •    Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Sanofi-Aventis lifts outlook as Q3 profit rises
    Sanofi-Aventis raises 2010 earnings guidance as 3rd quarter profit, sales rise
    
    .
    Thursday October 28, 2010, 3:49 am
    PARIS (AP) -- French pharmaceutical company Sanofi-Aventis SA said Thursday its net profit rose 13 percent in the third quarter thanks to strong demand in emerging markets and acquisitions in the consumer health care field.
    
    Sanofi-Aventis reported net profit of euro1.6 billion ($2.2 billion), up from euro1.4 billion a year earlier. Sales rose 5.7 percent to euro7.8 billion, as a stronger dollar offset weaker sales of core brands like the anticlotting drug Lovenox and blood thinner Plavix.
    
    The company, based in Paris, now expects core earnings to grow between 0 and 2 percent this year at constant exchange rates, compared with a previous forecast of a decline of between zero and 4 percent.
    
    Sanofi-Aventis shares gained on the news, rising 1.3 percent to euro50.15 in early trading on the Paris stock exchange.
    
    These core earnings, which Sanofi-Aventis calls business earnings per share, were up 6 percent at constant exchange rates in the nine months to September.
    
    Chief Executive Christopher Viehbacher said the company was on track to achieve more than the targeted euro1.2 billion in cost savings this year.
    
    In a conference call with reporters, Viehbacher also defended Sanofi-Aventis' $18.5 billion takeover bid for U.S. biotechnology firm Genzyme Corp.
    
    "Our euro69 cash offer is extremely compelling," Viehbacher said, "and nothing in what Genzyme has said in recent weeks would cause us to change our offer."
    
    Last week Genzyme said its own forecast for 2011 earnings made it worth euro89 a share.
    
    Genzyme is currently in a tussle with Sanofi-Aventis after the French drug developer initiated a hostile takeover bid which Genzyme's board has voted unanimously to recommend that shareholders reject. Sanofi-Aventis initially made the offer privately in July, then repeated it publicly in late August, but was rebuffed by Genzyme's board twice.
    
    Viehbacher also said that he'd had "no recent contact" with Genzyme CEO Henri A. Termeer, but that he's "hoping to hear from him."
    
    The buyout offer for Genzyme closes Dec. 10.
    
    Sales of Sanofi-Aventis' core pharmaceuticals, which includes blockbuster injected anticlotting drug Lovenox and blood thinner Plavix, the world's second bestselling drug, continued to suffer from generic competition in the third quarter. Sales of the company's 15 flagship drugs fell 3.5 percent to euro6.6 billion.
    
    Like other major international pharmaceutical companies, Sanofi has increasingly been making deals to acquire small companies or rights to promising experimental drugs. The moves are aimed at offsetting inadequate progress from internal research programs and looming revenue declines as blockbuster drugs face generic competition.
    
    Since he became Sanofi's CEO in December 2008, Viehbacher has arranged dozens of mostly mid-sized acquisitions. Those include a $1.9 billion March deal in which the company bought Tennessee-based Chattem Inc., maker of Gold Bond skin products and Icy Hot pain relief packs, in a strategy to expand its U.S. health care business.
    
    Sanofi-Aventis is the world's fourth-biggest pharmaceutical company, with 2009 revenue of about $35.5 billion. Genzyme booked 2009 net income of $422.3 million on revenue of $4.52 billion.
    
    DRW
17. [verwijderd] 3 november 2010 12:53

    auteur info

    •    [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    •    Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Sanofi CEO: No Movement In Genzyme Bid
    
    Last update: 11/2/2010 1:55:26 PM
    
    CLEVELAND (Dow Jones)--Sanofi-Aventis SA (SNY) Chief Executive Chris Viehbacher said Tuesday there has been no movement since last week in the drug maker's hostile bid for biotech company Genzyme (GENZ).
    
    Last week Viehbacher said Sanofi was sticking to its $69-per-share offer for Genzyme. and he proposed forming a "working group" with Genzyme to discuss issues related to the bid, including Genzyme's forecast of product sales.
    
    Genzyme has rejected Sanofi's offer, and recently suggested that its 2011 financial forecast implies that the company is worth closer to $89 per share. At a health-care conference at the Cleveland Clinic, Viehbacher told Dow Jones Newswires nothing had changed.
    
    In a question-an-answer session at the conference, he said Sanofi has been behind in its biotechnology efforts and acquiring Genzyme would "accelerate our entry."
    
    -By Peter Loftus, Dow Jones Newswires; 215-656-8289; Peter.loftus@dowjones.com (END)
    
    Dow Jones Newswires
    
    November 02, 2010 13:55 ET (17:55 GMT)
18. [verwijderd] 8 november 2010 19:11

    auteur info

    •    [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    •    Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Viesbacher blijft het slechte voorbeeld geven hoe een overname NIET moet gaan.
    En J&J maar gniffelen.
    
    UPDATE: Sanofi Renews Call For Genzyme To Open Takeover Talks
    Last update: 11/8/2010 11:56:56 AM
    
    PARIS (Dow Jones)--French drugs giant Sanofi-Aventis (SNY) Monday renewed calls for talks with its takeover target, U.S.-based Genzyme (GENZ), and urged the biotech to abandon strategies that would prevent shareholders from voting on its offer.
    
    In a letter addressed to Genzyme Chief Executive Henri Termeer, Sanofi's Chief Executive Chris Viehbacher said the French company "remains ready and willing to participate" in meetings that would provide some "limited due diligence regarding manufacturing or arranging a meeting with your commercial team" to go over prospects for the drug Campath.
    
    The two sides don't agree on the value of Genzyme's efforts to resolve manufacturing problems plaguing its Allston, Mass. plant, nor on the potential of Campath, known also as alemtuzumab and which Genzyme wants to market as a multiple sclerosis treatment.
    
    The U.S. biotech recently held a series of meetings with shareholders outlining its view on future prospects and has thus far declined a request from Sanofi for further information on the two issues. In his letter Monday, Viehbacher said Genzyme's 14D-9 response to Sanofi's $18.5 billion offer, launched Oct. 4, was inconsistent with the objective of maximising shareholder returns, citing poison pill tactics the biotech said it could employ regardless of shareholder support for the transaction.
    
    Any moves by Genzyme's board to stagger terms of its members and increase terms for two-thirds of the board by one to three years would not be appropriate, Sanofi said in the letter.
    
    The French pharmaceuticals giant also took issue with the potential use of a poison pill or the use of anti-takeover statutes in Massachusetts law, saying shareholders should be allowed to decide on Sanofi's proposal. Genzyme should confirm all board directors will be reelected at the annual meeting on May 26 next year and "take action" to make anti-takeover statute of Massachusettes law inapplicable to Sanofi's offer, it added.
    
    Monday's letter did not show signs the French company plans to raise its $69 per share offer, which is set to expire on Dec 10, to levels the market expects for a deal, repeating its view the offer reflects Genzyme's business and pipeline. Viehbacher said Sanofi still prefers to work with Genzyme in order to reach a "mutually agreeable transaction."
    
    At 1638 GMT, Sanofi shares traded up 0.1% at EUR51.03, slightly above the Paris CAC-40 index, down 0.1%. Genzyme shares traded down 0.7% at $71.18. By Mimosa Spencer,
    
    Dow Jones Newswires; +33 1 40 17 1773; mimosa.spencer@dowjones.com
19. pardon 8 november 2010 23:39

    auteur info

    •    pardon

      Lid sinds: 19 jan 2004

      Laatste bezoek: 12 sep 2022

    •    Aanbevelingen

      Ontvangen: 1387

      Gegeven: 2812

    •    Aantal posts: 16.824

    Door Mimosa SPENCER
    
    PARIJS-Franse drugs gigantische Sanofi-Aventis op maandag hernieuwde oproepen voor gesprekken met de overname doelwit, de VS gevestigde biotechbedrijf Genzyme Corp, en drong er bij het bedrijf om strategieën die aandeelhouders zouden beletten van de stemming over haar aanbod af te zien.
    
    In een brief gericht aan Genzyme Chief Executive Henri Termeer, Sanofi Chief Executive Chris Viehbacher zei het Franse bedrijf "blijft klaar en bereid om deel te nemen" in vergaderingen dat sommige "beperkte due diligence over de produktie of het regelen van een vergadering zou ...
20. flosz 15 november 2010 09:04

    auteur info

    •    flosz

      Lid sinds: 13 feb 2008

      Laatste bezoek: 01 jul 2024

    •    Aanbevelingen

      Ontvangen: 5298

      Gegeven: 2795

    •    Aantal posts: 7.005

    Sanofi's Shantha Vaccine Deal Fails to Bring Sales Boost Amid Factory Snag
    Sanofi-Aventis SA’s 440-million-euro ($602 million) acquisition of Indian vaccine maker Shantha Biotechnics Ltd. failed to live up to analyst forecasts after manufacturing woes wiped out $340 million of sales.
    The World Health Organization on July 28 dropped Shantha’s Shan5 vaccine for five childhood diseases from its list of shots that are approved for sale to agencies such as the United Nations Children’s Fund after white sediment was found in some vials. The suspension has cost France’s biggest drugmaker the $340 million in sales it planned to book from 2010 to 2012 from a contract with Unicef, said Pascal Barollier, a spokesman for the company’s Sanofi Pasteur vaccine unit in Lyon.
    The shot will be off the market until 2013 while Sanofi sorts out the manufacturing problem and resubmits the vaccine to the WHO for approval, he said in a Nov. 8 phone interview. The company touted Shantha’s “state-of-the-art manufacturing facilities” in announcing the purchase in July 2009 and said the Indian company’s $90 million of annual sales would “grow significantly.”
    The company is “doing everything possible” to implement corrective measures, Barollier said. Sanofi previously hadn’t disclosed publicly when sales of the vaccine would resume or that the company had lost all the revenue from the Unicef contract.
    Acquisitions are part of Chief Executive Officer Chris Viehbacher’s strategy to replace revenue the company is losing to competition from generic medicines. Sanofi is attempting an $18.5 billion hostile takeover of Genzyme Corp., a U.S. biotechnology company with its own manufacturing woes.
    Genzyme’s Woes
    Genzyme’s shares slumped as much as 43 percent from their 2008 high after a viral contamination last year at a company plant in Boston led to drug shortages.
    “We remain to be convinced that Sanofi-Aventis will be able to add material skill in resolving Genzyme’s manufacturing issues: we note that the Shantha vaccines purchase of 2009 still has production difficulties,” Michael Leacock, an analyst at Royal Bank of Scotland in London, wrote in an Aug. 31 note to clients. He has a “buy” recommendation on Sanofi shares.
    Sanofi took a 108-million-euro charge in the second quarter primarily to write down the value of Shan5, and another 171- million-euro impairment in the third quarter for products including the shot. The company declined to be more specific.
    Five in One
    Shan5 is a so-called pentavalent vaccine that provides protection against five diseases -- diphtheria, whooping cough, tetanus, haemophilus influenza B, and hepatitis B. The shot, produced by Shantha at a plant in Hyderabad, India, is used in poor nations including Chad and the Central African Republic. The WHO, an arm of the United Nations, “pre-qualifed” the shot, which is a prerequisite for sales to supranational organizations such as Unicef.
    In September 2009, Sanofi announced that Shantha had won the Unicef contract to provide Shan5 from 2010 to 2012. The WHO temporarily suspended the vaccine in March this year because of the sediment as a “precautionary measure pending outcome of an investigation of vaccine quality,” Sanofi said at the time. The sediment wasn’t linked to any health risks.
    The WHO removed Shan5’s pre-qualification on July 28 because of the sediment problem and recommended the use of competing products, according to a statement on the agency’s website. The decision, which wasn’t announced by Sanofi, means Unicef can no longer acquire the vaccine.
    ‘High-Quality Investigation’
    Sanofi “conducted a high-quality investigation” to solve Shan5’s white-sediment problem and submitted a “robust plan for corrective action,” according to the statement. However, the corrective measures require a new application for pre- qualification, the agency said.
    The vaccine with sediment was manufactured before Sanofi bought Shantha, Wayne Pisano, Sanofi’s senior vice president for vaccines, said on a July 29 conference call with analysts for second-quarter earnings.
    Sanofi booked none of the $340 million before the WHO suspended use of the shot, Barollier said. Sanofi had 29.3 billion euros of revenue last year.
    The WHO determined that the sediment originated with the whooping cough component of the vaccine. The agency suspended the pre-qualification of a four-in-one Shantha inoculation that also uses the whooping cough shot, and halted the approval process for a three-in-one shot.
    Sanofi’s Barollier declined to say what Shantha’s sales would be this year or next.
    ‘Soft Spot’
    Seamus Fernandez, an analyst at Leerink Swann & Co., cut his 2010 revenue forecast for Shantha in June to zero from 105 million euros, and lowered his predictions for the next five years as well.
    Sanofi has a mostly good track record in licensing or buying new medicines, Andrew Baum, an analyst at Morgan Stanley, wrote in a report last month. “The Shantha acquisition remains the only obvious soft spot in the company’s in-licensing campaign,” he wrote.
    The manufacturing snag is manageable for Sanofi, said Jerome Forneris, who helps manage $11 billion, including Sanofi shares, at Banque Martin Maurel in Marseille, France.
    “Sanofi Pasteur is one of the world’s biggest vaccine makers,” Forneris said in a Nov. 10 phone interview. “They have in-house experts who know how to solve these kinds of problems. Vaccine making is a complicated process and problems of this kind do pop up every once in a while.”
    Quinvaxem
    SHAN5 ISN’T THE ONLY PENTAVALENT VACCINE FACING PROBLEMS. CRUCELL NV HALTED PRODUCTION OF THE COMPETING QUINVAXEM LAST MONTH BECAUSE OF A MICROBIOLOGICAL CONTAMINATION AT THE SOUTH KOREA PLANT MAKING THE PRODUCT. LEIDEN, NETHERLANDS-BASED CRUCELL REPORTED A THIRD-QUARTER LOSS ON NOV. 9 AFTER WRITING DOWN THE VALUE OF QUINVAXEM INVENTORIES. THE COMPANY SAID IT EXPECTED TO RESUME OUTPUT “IN THE COMING WEEKS.”
    GlaxoSmithKline Plc, Panacea Biotec and the Serum Institute of India are the other makers of pentavalent vaccines approved by the WHO. THE LACK OF SHAN5 AND QUINVAXEM HASN’T CAUSED SHORTAGES SO FAR, ACCORDING TO ALISON BRUNIER, A SPOKESWOMAN FOR THE AGENCY.
    Unicef awarded contracts to supply the vaccine for a three- year period, from 2010 to 2012, according to Joan Howe, a spokeswoman for the agency. The organization may need to buy more supply for use in 2012, she said. In 2012, Unicef also will begin seeking bids for the next multi-year contracts that commence in 2013, she said. Sanofi expects to be able to bid for those multi-year contracts, Barollier said.
    www.bloomberg.com/news/2010-11-14/san...
    *****************************
    
    Genzyme in Talks With Takeda About $18.5 Billion Sale, Mail on Sunday Says
    www.bloomberg.com/news/2010-11-14/gen...